Evidence map›Paper›PMID 39576229›Full record

ArticleClinical and translational medicine2024

Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model.

Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Xiaoqiong Zhu, Lirong Liu, Mei Zhou, Li Zhang and 42 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. EarlyCancers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Tian ZengDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiudi YangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yi WangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Dijiong WuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Weiying FengCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Ying LuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xiaoqiong ZhuZhejiang Clinical Medical Research Center of Hematology, Hangzhou, China.
Lirong LiuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Mei ZhouCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Li ZhangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yanping ShaoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Honglan QianCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Feng ZhuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yu ChenCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Dan CaoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Li HuangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xiaoning FengCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Lili ChenCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Gang ZhangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Jing LeCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Weiguo ZhuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yongming XiaCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yanxia HanCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yongqing JiaCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Guoyan TianCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Hui ZhouCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Linjuan XuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xiufeng YinCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Qinli TangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Yuefeng ZhangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Guoli YaoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xianghua LangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Kaifeng ZhangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xiujie ZhouCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Junbin GuoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Jinming TuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Jianzhi ZhaoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Gongqiang WuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Huiqi ZhangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Xiao WuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Qiulian LuoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Lihong CaoCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Binbin ChuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Wei JiangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Haiying WuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Liansheng HuangCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Meiwei HuCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Muqing HeCML Cooperation Group of Zhejiang Hematology, Zhejiang, China.
Jingjing ZhuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-8166-9915
Jian HuangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0003-4200-8636

Funding

Key R&D Program of Zhejiang 2022C03137Zhejiang Medical Association Clinical Medical Research Special Fund Project 2022ZYC-D09
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39576229
PMCPMC11583811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.